Key Points

  • Nearly 25% of PET2 patients relapsed, demonstrating limitations of frontline ABVD and low negative predictive value of PET2.

  • In patients with a positive PET2 who received eBEACOPP, PFS was favorable, but was associated with a high rate of second cancers.

Abstract

Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)–adapted therapy on SWOG S0816. Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 additional cycles of ABVD. Patients not achieving CR on PET2 were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles. After a median follow-up of 5.9 years, a subset of 331 eligible patients with central review of PET2 was analyzed. PET2 was negative in 82% and positive in 18%. For all patients, the estimated 5-year PFS and OS was 74% (95% confidence interval [CI], 69%-79%) and 94% (95% CI, 91%-96%), respectively. For PET2 and PET2+ patients, the 5-year PFS was 76% (95% CI, 70%-81%) and 66% (95% CI, 52%-76%), respectively. Seven (14%) and 6 (2%) patients reported second cancers after treatment with eBEACOPP and ABVD, respectively (P = .001). Long-term OS of HL patients treated on S0816 remains high. Nearly 25% of PET2 patients experienced relapse events, demonstrating limitations ABVD therapy and of the negative predictive value of PET2. In PET2+ patients who received eBEACOPP, PFS was favorable, but was associated with a high rate of second malignancies compared with historical controls. Our results emphasize the importance of long-term follow-up, and the need for more efficacious and less toxic therapeutic approaches for advanced-stage HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00822120.

REFERENCES

REFERENCES
1.
Duggan
DB
,
Petroni
GR
,
Johnson
JL
, et al
.
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial
.
J Clin Oncol
.
2003
;
21
(
4
):
607
-
614
.
2.
Gordon
LI
,
Hong
F
,
Fisher
RI
, et al
.
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
.
J Clin Oncol
.
2013
;
31
(
6
):
684
-
691
.
3.
Sieniawski
M
,
Reineke
T
,
Nogova
L
, et al
.
Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)
.
Blood
.
2008
;
111
(
1
):
71
-
76
.
4.
Engert
A
,
Diehl
V
,
Franklin
J
, et al
.
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study
.
J Clin Oncol
.
2009
;
27
(
27
):
4548
-
4554
.
5.
Borchmann
P
,
Haverkamp
H
,
Lohri
A
, et al
.
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
.
Lancet Oncol
.
2017
;
18
(
4
):
454
-
463
.
6.
Juweid
ME
,
Stroobants
S
,
Hoekstra
OS
, et al;
Imaging Subcommittee of International Harmonization Project in Lymphoma
.
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
.
J Clin Oncol
.
2007
;
25
(
5
):
571
-
578
.
7.
Oki
Y
,
Chuang
H
,
Chasen
B
, et al
.
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma
.
Br J Haematol
.
2014
;
165
(
1
):
112
-
116
.
8.
Gallamini
A
,
Hutchings
M
,
Rigacci
L
, et al
.
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study
.
J Clin Oncol
.
2007
;
25
(
24
):
3746
-
3752
.
9.
Hutchings
M
,
Loft
A
,
Hansen
M
, et al
.
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
.
Blood
.
2006
;
107
(
1
):
52
-
59
.
10.
Press
OW
,
Li
H
,
Schöder
H
, et al
.
US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: Southwest Oncology Group S0816
.
J Clin Oncol
.
2016
;
34
(
17
):
2020
-
2027
.
11.
Johnson
P
,
Federico
M
,
Kirkwood
A
, et al
.
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma
.
N Engl J Med
.
2016
;
374
(
25
):
2419
-
2429
.
12.
Gallamini
A
,
Tarella
C
,
Viviani
S
, et al
.
Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial
.
J Clin Oncol
.
2018
;
36
(
5
):
454
-
462
.
13.
Cheson
BD
,
Pfistner
B
,
Juweid
ME
, et al;
International Harmonization Project on Lymphoma
.
Revised response criteria for malignant lymphoma
.
J Clin Oncol
.
2007
;
25
(
5
):
579
-
586
.
14.
Evens
AM
,
Antillón
M
,
Aschebrook-Kilfoy
B
,
Chiu
BC
.
Racial disparities in Hodgkin’s lymphoma: a comprehensive population-based analysis
.
Ann Oncol
.
2012
;
23
(
8
):
2128
-
2137
.
15.
Kahn
JM
,
Keegan
TH
,
Tao
L
,
Abrahão
R
,
Bleyer
A
,
Viny
AD
.
Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma
.
Cancer
.
2016
;
122
(
17
):
2723
-
2730
.
16.
Maggioncalda
A
,
Malik
N
,
Shenoy
P
,
Smith
M
,
Sinha
R
,
Flowers
CR
.
Clinical, molecular, and environmental risk factors for Hodgkin lymphoma
.
Adv Hematol
.
2011
;
2011
:
736261
.
17.
Scott
DW
,
Chan
FC
,
Hong
F
, et al
.
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma
.
J Clin Oncol
.
2013
;
31
(
6
):
692
-
700
.
18.
Scott
DW
,
Li
H
,
Harvey
Y
, et al
.
The 23-gene gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US Intergroup S0816 trial
.
Hematol Oncol
.
2017
;
35
(
suppl 2
):
92
-
93
.
19.
Steidl
C
,
Lee
T
,
Shah
SP
, et al
.
Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma
.
N Engl J Med
.
2010
;
362
(
10
):
875
-
885
.
20.
Hsi
ED
,
Li
H
,
Nixon
AB
, et al
.
Prognostic utility of serum TARC, MDC, IL10, and soluble CD163 levels with positron emission tomography (PET) response-adapted therapy for advanced-stage Hodgkin lymphoma (HL): a SWOG S0816 US intergroup correlative study
.
Blood
.
2017
;
130
(
suppl 1
):
4033
-
4033
.
21.
Spina
V
,
Bruscaggin
A
,
Cuccaro
A
, et al
.
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
.
Blood
.
2018
;
131
(
22
):
2413
-
2425
.
22.
Zasadny
KR
,
Kison
PV
,
Francis
IR
,
Wahl
RL
.
FDG-PET determination of metabolically active tumor volume and comparison with CT
.
Clin Positron Imaging
.
1998
;
1
(
2
):
123
-
129
.
23.
Larson
SM
,
Erdi
Y
,
Akhurst
T
, et al
.
Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG Imaging. The Visual Response Score and the change in total lesion glycolysis
.
Clin Positron Imaging
.
1999
;
2
(
3
):
159
-
171
.
24.
Cottereau
AS
,
Versari
A
,
Loft
A
, et al
.
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
.
Blood
.
2018
;
131
(
13
):
1456
-
1463
.
25.
Song
MK
,
Chung
JS
,
Lee
JJ
, et al
.
Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma
.
Cancer Sci
.
2013
;
104
(
12
):
1656
-
1661
.
26.
Kanoun
S
,
Rossi
C
,
Berriolo-Riedinger
A
, et al
.
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
.
Eur J Nucl Med Mol Imaging
.
2014
;
41
(
9
):
1735
-
1743
.
27.
Moskowitz
AJ
,
Schöder
H
,
Gavane
S
, et al
.
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
.
Blood
.
2017
;
130
(
20
):
2196
-
2203
.
28.
Akhtari
M
,
Milgrom
SA
,
Pinnix
CC
, et al
.
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation
.
Blood
.
2018
;
131
(
1
):
84
-
94
.
29.
Kobe
C
,
Goergen
H
,
Baues
C
, et al
.
Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma
.
Blood
.
2018
;
132
(
21
):
2273
-
2279
.
30.
Viviani
S
,
Zinzani
PL
,
Rambaldi
A
, et al;
Intergruppo Italiano Linfomi
.
ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned
.
N Engl J Med
.
2011
;
365
(
3
):
203
-
212
.
31.
Skoetz
N
,
Will
A
,
Monsef
I
,
Brillant
C
,
Engert
A
,
von Tresckow
B
.
Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
.
Cochrane Database Syst Rev
.
2017
;
5
:
CD007941
.
32.
Connors
JM
,
Jurczak
W
,
Straus
DJ
, et al;
ECHELON-1 Study Group
.
Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma
.
N Engl J Med
.
2018
;
378
(
4
):
331
-
344
.
33.
Ramchandren
R
,
Advani
RH
,
Ansell
SM
, et al
.
Brentuximab vedotin plus chemotherapy in North American subjects with newly diagnosed stage III or IV Hodgkin lymphoma
.
Clin Cancer Res
.
2019
;
25
(
6
):
1718
-
1726
.
34.
Connors
JM
,
Younes
A
,
Gallamini
A
, et al
.
Brentuximab vedotin plus chemotherapy in patients with advanced-stage classical Hodgkin lymphoma (cHL): evaluation of modified progression-free survival (mPFS) and traditional PFS in the phase 3 ECHELON-1 study
[abstract].
Blood
.
2018
;
132
(
suppl 1
). Abstract
2904
.
35.
Ramchandren
R
,
Domenech
ED
,
Rueda
A
, et al
.
CHECKMATE 205 Cohort D: A Phase 2 Trial of Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma
.
Stockholm, Sweden
:
European Haematology Association
;
2018
.
36.
Borchmann
P
,
Haverkamp
H
,
Diehl
V
, et al
.
Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group
.
J Clin Oncol
.
2011
;
29
(
32
):
4234
-
4242
.
37.
Engert
A
,
Haverkamp
H
,
Kobe
C
, et al;
Arbeitsgemeinschaft Medikamentöse Tumortherapie
.
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
.
Lancet
.
2012
;
379
(
9828
):
1791
-
1799
.
You do not currently have access to this content.